A Contract Research and
                  Development Company
Chemistry Banner

New at Organix


  • Raj Razdan, Co-founder and CEO (1986-2009) of Organix, died peacefully in his sleep on November 10, 2018 at the age of 89.

    Raj obtained his PhD from the University of Glasgow. In 1963 he moved to the US and he spent six years at Arthur D. Little where he first began his work on cannabinoids. He developed the first large-scale one step synthesis of THC and kilogram quantities became available for research. His research laid the foundation for the basic understanding of the pharmacology and toxicology of cannabinoids. In 1970, Raj co-founded SISA in Cambridge, MA where he spent 15 years working on cannabinoids.

    In 1986, Raj co-founded Organix, and for 23 years Raj was a driving force and inspiration behind Organix. Raj always saw the glass as half full, and his infectious optimism was felt by everyone he worked with. Raj was a superb bench chemist, and he worked in the lab throughout his time at Organix, while at the same time writing and supervising NIH grants and helping to run the custom synthesis side of the company.

    Raj's optimism, kindness, humility and great sense of humor will be sorely missed by his family at Organix.

    Rest in Peace Raj.

  • Organix is proud to have been a sponsor of the mRNA conference in Boston. Organix has many years of experience in lipid synthesis and has been supplying lipids to the mRNA community for over ten years. If you attended the International mRNA Health Conference and want more information about Organix please contact Organix at info@organixinc.com.

  • Dr. Peter Meltzer, Co-Founder, President & CEO of Organix, Inc. retired in August 2018. Dr. Anu Mahadevan and Dr. Paul Blundell have assumed leadership roles at Organix. Dr. Howard Sard, a co-founder of Organix, will continue to help lead Organix.

    As co-founder and President of Organix, Dr. Meltzer has had the privilege to lead Organix to the point where it is now recognized as a premier Contract Research Organization providing chemistry and discovery services in the United States. Dr. Meltzer said that he is particularly proud of the fact that over the past 32 years over 200 companies have accessed our services and that Organix has contributed substantially to the discovery and the development of new chemical entities for our clients. Organix is recognized as one of the first companies to have provided such services in the US. Among these services are Custom Synthesis, Design and Synthesis of New Chemical Entities, Medicinal Chemistry, Structure Activity Relationship Studies, Hit-to-Lead Studies, Development and Optimization of Synthetic Procedures and Moderate Scale-up.

    Dr. Meltzer would like to thank our clients for their confidence in Organix over the many years. He said he is absolutely certain that our new leadership will bring Organix to new heights as they introduce new programs and services that will continue to propel Organix forward in exciting ways.

  • Many thanks to the ACS for an excellent meeting in Boston. Organix was an exhibitor at the 256th ACS National Meeting & Exposition. We enjoyed chatting with current clients who visited us. We made many new contacts and we look forward to helping our new contacts discover how Organix can help in their chemistry needs. Contact Organix at info@organixinc.com to receive more information about our services.

  • Tarik Soliman and Laura Hales of Extend Biosciences recently acknowledged the contribution Organix made to their Therapeutic Vitamin D Conjugates patent. This cutting edge research was patented and the patent has just been published US9,585,934.

  • Organix is proud to announce that Akebia Therapeutics is continuing its collaboration with Organix for 2017. Organix clients range from big Pharma & Biotech companies to small start-up companies & virtual biotech companies. Please contact Organix and find out how we can move your project forward. From large to small, all projects get our full attention.

  • Organix has considerable experience with the microencapsulation of a variety of drugs. Our expertise includes the preparation of gels and other inert polymeric coatings for chemotherapeutic agents, opioids for pain management, and other pharmaceutical agents where controlled release via biodegradation is desired. We optimize experimental conditions to vary the size and loading of the microspheres obtained, carry out time release studies at ambient and elevated temperatures. Stability studies and evaluation of drug halflives are conducted.

    Organix has been part of a study that was reported recently on microencapsulation of Cisplatin.

  • SharpEdge logo1 AND logo1 SIGN A CONTRACT...

  • Organix and Sharp Edge Labs have signed a contract to provide key intermediates to create general purpose immunosensors. Sharp Edge Labs is a provider of enabling technologies for the drug discovery industry and is pioneering a new class of biosensors developed at Carnegie Mellon University in the laboratories of Dr. Alan Waggoner and Dr. Marcel Bruchez. The Company's president and CEO, Dr.Scott Sneddon is the PI on an SBIR grant (1R43CA171427-01) awarded to fund the "Fluorogenic Molecular Proximity Detection Platform."

    "I've known and worked with Dr. Paul Blundell of Organix over many years, first at Genzyme's Drug Discovery Group, and now at Sharp Edge, and I've always found Paul and his team to be great collaborators, and an extension of our own chemistry team," said Sneddon. "We're looking forward to developing key aspects of a new and exciting method of antibody detection that greatly simplifies the experiment, making it amenable to high-throughput, as well as increasing specificity," he added.

    Organix will be responsible for a significant portion of the chemistry effort, with Sharp Edge contributing the biology portion of the project at its laboratories in Pittsburgh, PA. Dr. Blundell stated "It is great to see clients returning to Organix for services. This is a clear endorsement of the quality of chemistry and people at Organix and is always appreciated." Blundell added "Our team is excited to be involved in the development of Sharp Edge Lab's innovative Detection Platform."

  • Jeffrey Hrkach of Bind Biosciences and coauthors (including MIT's Robert Langer) recently acknowledged the contribution Organix made to their cutting edge PSMA-Targeted Docetaxel Nanoparticle research. Organix was acknowledged for our work in synthesizing the monomer that was used in the synthesis of the PLA-PEG-ACUPA targeting polymer that was used in the reported study.

  • Peter Meltzer, President & CEO of Organix, was recently interviewed by CEOCFO magazine. He took pleasure in describing Organix and the way Organix works hand-in-hand with its clients to provide exceptional chemistry service. He went on to discuss how Organix competes effectively with foreign competition and succeeds in securing projects. For a full description of the interview please visit the CEOCFO website or click on the link interview. For more information about how Organix can help your projects please contact Dr. Meltzer at info@organixinc.com

  • Covidien, a client of Organix, recently presented a poster at the World Conference on Interventional Oncology (WCIO 2012, poster#53-page 67). Organix helped Covidien develop a microencapsulation based formulation of cisplatin that allows the sustained-release of the anti-cancer drug, cisplatin. This offers the potential for greater efficacy and reduced systemic toxicity. WCIO is a scientific forum designed to support Interventional Oncology (IO) therapies and is the perfect place to present such ground breaking discoveries. Organix is proud to be an enthusiastic collaborator in Covidien's cutting edge discoveries.

  • Professor Alexandros Makriyannis recently visited Organix. He presented an overview of the latest advances to emerge from his laboratories in the cannabinoid field. Professor Makriyannis holds the George D. Behrakis Chair in Pharmaceutical Biotechnology and is Director of Northeastern University's Center for Drug Discovery. Professor Makriyannis is internationally recognized as a leader in the field of cannabinoids, their biological activity, and their modes of action. His research interests include investigation of cannabinergic drugs that modulate the central nervous system and the immune system. His group has recently made exciting advances in the discovery and development of potential pharmacotherapies that target cannabinoid receptors.

    • Alex_and_Anu

    • Professor Makriyannis and Organix' Vice President, Anu Mahadevan

  • Organix exhibited at the 2012 BioInternational Convention held in Boston in June. Organix met many prospective new clients and also reconnected with clients who have used our services previously. We look forward to helping our new contacts discover how Organix can help move their projects forward rapidly and effectively!

    • bio_booth_2012

    • Organix Booth at BioInternational 2012

  • Navidea signs option agreement to license Parkinson’s imaging agent from Alseres. Altropane is a radiopharmaceutical used with Single-Photon Emission Computed Tomography (SPECT) imaging to identify the status of areas of the brains in patients suspected of having Parkinson’s disease, a nervous system disorder that leads to shaking known as tremors and difficulty in movement. The imaging agent works by binding to the dopamine transporter on nerve cells in the brain. Altropane was invented by a collaboration of scientists at Organix, Harvard Medical School, Massachusetts General Hospital, and Northeastern University, and licensed to Alseres. http://www.medcitynews.com/2012/01/navidea

  • Boston Business Journal interviews Dr. Meltzer, CEO of Organix, on the state of CROs in the Boston area. http://www.bizjournals.com/boston/

  • Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity. http://www.biospace.com/news_story

Selected Publications

  • "3-Substituted Pyrazole Analogs of the Cannabinoid Type 1 (CB1) Receptor Antagonist Rimonabant: Cannabinoid Agonist-Like Effects in Mice via Non-CB1, Non-CB2 Mechanism", Wiley, J. L.; Selley, D. E.; Wang, P.; Kottani, R.; Gadthula, S.; Mahadevan, A.; J. Pharmacol. Exper.Ther., 2012, 340(2), 433.

  • 8-Tetrahydrocannabivarin protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress and inflammatory response involving CB2 receptors ", Batkai, S.; Mukhopadhyay, P.; Horvath, B.; Rajesh, M.; Gao, R. Y.; Mahadevan, A.; Amere, M.; Battista, N.; Lichtman, A. H.; Gauson, L. A.; Maccarrone, M.; Pertwee, R. G.; Pacher, P.; Br. J. Pharmacol ., 2011, 6.

  • "Inhibition of monoacylglycerol lipase (MAGL) attenuates NSAID-induced gastrichemorrhages in mice ", Kinsey, S. G.; O’Neal, S. T.; Nomura, D. K.; Long, J. Z.; Mahadevan, A.; Cravatt, B. F.; Grider, J. R.; Lichtman, A. H.; J. Pharmacol. Exper.Ther ., 2011, 338(3), 795.

  • "The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes", Purushotham, M.; Sheri, A.; Pham-Huu, D-P.; Madras, B. K.; Janowsky, A.; Meltzer, P.C. Bioorg. & Med. Chem. Lett., 2011, 21, 48.

Back to Top

Research at Organix